Name | Type | Posted | Actions |
|---|---|---|---|
NOI HT941026N0064 Reagents and Maintenance Service for Flow Cytometry Instruments.docx | DOCX | May 19, 2026 |
Reagents and Maintenance Service for Flow Cytometry Instruments
Contact and place of performance
Jason Willey
WA 98431
USA
THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE PURCHASE ORDER CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES . The Defense Health Agency Contracting Activity (DHACA), Healthcare Contracting Division - West (HCD-W), Echo Branch intends to negotiate and award a firm-fixed price purchase order (PO) contract for the provision of all services, materials, and equipment necessary to provide required Reagents...
View moreRequirement Description Product Number Quantity
Anti-Kappa-FITC (Goat Polyclonal), 2ml ASR C15623 2
Anti-Lambda-PE (Goat Polyclonal), 2ml ASR C15189 2
FMC7-FITC, 1ML, ASR IM1364U 2
MYELORPEROXIDASE-RPE, 2ML, ASR IM3455U 2
7-AAD Viability Dye 150t CE A07704 4
CD1a-APC , 1ML, ASR IM3645 2
Anti-TdT (POOL)-FITC, 1ML, ASR IM3524U 2
CD2-Pacific Blue, 0.5ML ASR B09685 2
CD3-ECD, 1ML, ASR IM2705U 2
CD3-FITC, 2ML, ASR IM1281U 2
CD4-APC-Alexa Fluor 700, 0.5ML ASR B10824 2
CD5-PC5.5, 0.5ML ASR A70203 2
CD7-PC7, 1ML ASR A46526 2
CD10-PC7, 1ML ASR A46527 2
CD11c-APCA700, 50t, ASR B43304 2
CD14-PC7, 1ML ASR A22331 2
CD16-APC, 0.5ML ASR B00845 2
CD19-APC, 1ML, ASR IM2470U 4
CD20-ECD, 1ML, ASR IM3607U 4
CD22-RPE, 2ML, ASR IM1835U 2
CD23-RPE, 2 ML ASR A33099 2
CD25-APC-Alexa Fluor 750, 0.5ML ASR B13979 2
CD26-RPE, 2ML, ASR IM2724 2
CD30-APC, 0.5ML ASR A87939 2
CD33-PC5.5, 0.5ML ASR A70198 2
CD34-APC-Alexa Fluor 750, 0.5ML ASR A89309 2
CD38-APC-Alexa Fluor 700, 0.5ML ASR B23489 2
CD45-Krome Orange, 1ML, AS A96416 4
CD56-PC7, 1ML ASR A51078 2
CD81-Pacific Blue, 0.5ML ASR B19717 2
CD79a-PC5.5, 50t, ASR B42018 2
CD103-FITC, 2ML, ASR IM1856U 2
CD117-ECD, 0.5ML ASR B38307 2
CD123-PC5.5, 0.5ML ASR B20022 2
CD138-PC5.5,0.5ML ASR A98835 2
CD45-FITC/CD56-PE/CD19-ECD/CD3-PC5 6607073 8
TETRA 45/4/8/3 6607013 8
FP,FLOW CHECK PRO IVD 3 X 10 ML KIT A63493 7
ISOFLOW(TM) EPICS SHEATH FL,10 8546859 20
FP, FLOW SET PRO IVD 3 X 10 ML KIT A63492 7
IMMUNO-TROL Low Cells 6607098 6
IMMUNO-TROL Cells 6607077 6
IntraPrep Permeabilization Reagent 50t CE A07802 2
ClearLLab 10C B Cell Tube B96805 15
ClearLLab 10C T Cell Tube B96806 15
ClearLLab 10C M1 Cell Tube B96807 6
ClearLLab 10C M2 Cell Tube B96808 6
PT Navios 3L 10C Service Contract B89707 1
CD57-FITC, 2ML, ASR IM0466U 2
IMMUNOPREP Reagent System 7546999 12
CD8-Pacific Blue, 0.5ML ASR A82791 2
Delivery Location:
MADIGAN ARMY MEDICAL CENTER
Bldg. 9040A Rm. G 3803
Tacoma, 98431
Delivery:
On or before: 9/30/2027
Based on market research and previous acquisition history, it has been determined that Beckman Coulter, Inc
is the only source that can meet the Government’s specialized requirement.
This notice of intent is not a request for competitive proposals, and no solicitation document exists for this requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to perform the required work. Capability statements shall not exceed six (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source purchase order.
If a vendor challenges the basis of this requirement, please email capability statements as a Microsoft Word or Adobe PDF attachment to Jason Willey at [email protected] and Tracy M. Robinson at [email protected]. The closing date for challenges is no later than 10:00 a.m. (Pacific Time), 1 June 2026
NO TELEPHONE REQUESTS/OFFERS WILL BE HONORED.
The Defense Health Agency (DHA), Healthcare Contracting Division - West (HCD-W), Echo Branch, intends to award a firm-fixed price, sole-source purchase order to Beckman Coulter, Inc. for reagents and maintenance services. This requirement supports the Department of Pathology, Core Laboratory Services at Madigan Army Medical Center in Tacoma, Washington. The scope includes the provision of all services, materials, and equipment necessary to maintain government-owned Navios 10 analyzers and TQ Prep workstations. Specifically, the contractor will supply specialized reagents, viability dyes, cell tubes, and testing materials required for flow cytometry, a critical process for identifying white blood cell alterations related to infectious diseases, autoimmune disorders, and immunodeficiencies.
The acquisition is classified under NAICS 325413 for In-Vitro Diagnostic Substance Manufacturing and PSC 6550 for In Vitro Diagnostic Substances, Reagents, Test Kits and Sets. In addition to providing consumables and maintenance services, the contract includes training for laboratory staff on the specified analyzers. The anticipated performance period requires delivery of all items and services on or before September 30, 2027.
This special notice, identified by solicitation number HT941026N0064, indicates that the government currently intends to proceed with a sole-source award as Beckman Coulter, Inc. is identified as the only source capable of meeting these specialized requirements. While this is not a request for competitive quotes, interested parties may submit a capability statement of no more than six pages to the primary point of contact, Jason Willey, by June 1, 2026, at 10:00 a.m. Pacific Time. The government will use submitted technical and cost information to determine whether a competitive procurement is warranted. Supporting documentation was published on May 19, 2026, including one attachment detailing the notice of intent.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.